Table 1.
Baseline characteristics of patients.
| Characteristics | Overall |
|---|---|
| n | 227 |
| Age (mean ± SD) | 41.89 ± 13.57 |
| Sex, female/male | 142/85 |
| BMI (mean ± SD) | 20.86 ± 1.63 |
| Weight (mean ± SD) | 61.33 ± 10.58 |
| Type of IBS (%) | |
| IBS with constipation | 108 (47.58) |
| IBS with diarrhea | 89 (39.21) |
| IBS mixed | 30 (13.22) |
| History of IBS-related medications (%) | |
| Laxatives | 132 (58.15) |
| Prokinetic drugs | 84 (37) |
| Antidiarrheal | 106 (47) |
| Psychotropic drugs | 97 (42.73) |
| Painkillers | 65 (28.63) |
| PPI | 183 (80.62) |
| Antibiotics | 152 (66.96) |
| Probiotics | 197 (86.78) |
| Traditional Chinese medicine | 118 (51.98) |
| Spasmolytic | 149 (65.64) |
| IBS-SSS score (mean ± SD) | 321.37 ± 73.89 |
| IBS-QoL score (mean ± SD) | 40.24 ± 11.34 |
| FAS score (mean ± SD) | 47 ± 8.64 |
| FMT pathway (%) | |
| Capsules | 63 (27.75) |
| Nasointestinal tube | 124 (54.63) |
| Colonoscopy | 40 (17.62) |
| Average course of FMT (times) | 3.93 ± 2.30 |
| Nasointestinal tube (times) | 3.83 ± 1.78 |
| Capsules (times) | 5.19 ± 2.94 |
| Colonoscopy (times) | 2.25 ± 1.24 |
BMI, body mass index; FMT, fecal microbiota transplantation; IBS-QoL, IBS-specific quality of life; IBS-SSS, IBS severity scoring system; PPI, proton pump inhibitor.